What are the newest treatments for Endometrial Cancer in 2026

Newest Endometrial Cancer Treatments in 2026

Based on the most current NCCN Guidelines (Version 1.2026), there have been significant advances in endometrial cancer treatment, particularly for advanced and recurrent cases. Here's what you need to know:

Immunotherapy + Chemotherapy Combinations (Most Recent Advances)

The biggest breakthrough in recent years has been combining immunotherapy drugs with traditional chemotherapy. According to NCCN Guidelines, these FDA-approved combinations are now standard options:

Dostarlimab + Chemotherapy (RUBY Trial)

• What it is: Dostarlimab is an immunotherapy drug (a checkpoint inhibitor) combined with carboplatin and paclitaxel chemotherapy
• When it's used: For advanced or recurrent endometrial cancer
• Why it works: The immunotherapy helps your immune system recognize and attack cancer cells that chemotherapy may miss
• Status: FDA-approved with strong clinical evidence showing improved overall survival

Pembrolizumab + Chemotherapy (KEYNOTE-B21 Trial)

• What it is: Another immunotherapy drug paired with carboplatin-paclitaxel chemotherapy, with or without radiation
• When it's used: For newly diagnosed high-risk endometrial cancer (after surgery)
• Status: FDA-approved as of 2024; represents a major shift toward combining immunotherapy with adjuvant (post-surgery) treatment

Durvalumab + Chemotherapy ± Olaparib (DUO-E Trial)

• What it is: Durvalumab (immunotherapy) plus chemotherapy, with the option to add olaparib (a PARP inhibitor that targets DNA repair)
• When it's used: First-line treatment for advanced endometrial cancer
• Status: FDA-approved; particularly useful for patients with mismatch repair deficiency

---

Targeted Therapies for Specific Biomarkers

Treatment is increasingly personalized based on your cancer's specific characteristics:

For Mismatch Repair-Deficient (MMR-d) or Microsatellite Instability-High (MSI-H) Cancers

If your tumor has these genetic features, you may be eligible for:

• Dostarlimab monotherapy (immunotherapy alone) - FDA-approved for recurrent/advanced MMR-deficient endometrial cancer
• Pembrolizumab monotherapy - For patients with MSI-H endometrial cancer
• Durvalumab - FDA-approved for MMR-deficient advanced or recurrent disease

Why this matters: These cancers respond exceptionally well to immunotherapy because they have many genetic mutations that the immune system can recognize.

For HER2-Overexpressing Cancers

• Trastuzumab deruxtecan - A newer targeted therapy for HER2-positive endometrial cancers (including uterine serous carcinomas)
• Trastuzumab + chemotherapy - Traditional approach for HER2-overexpressing advanced disease

For NTRK Fusion-Positive Cancers

• Repotrectinib - A newer targeted therapy for rare NTRK fusion mutations

---

Lenvatinib + Pembrolizumab (KEYNOTE-775)

• What it is: A combination of a targeted therapy (lenvatinib, which blocks multiple growth pathways) with immunotherapy
• When it's used: For previously treated advanced endometrial cancer
• Status: FDA-approved; now also being studied as first-line treatment with promising results
• Key advantage: Offers an option for patients who may not be candidates for chemotherapy

---

Hormone Therapy (Still Important for Specific Cases)

For lower-grade, early-stage endometrial cancers (especially in younger women wanting to preserve fertility):

• Progestin-based therapies: Megestrol acetate, medroxyprogesterone acetate
• Levonorgestrel IUD (intrauterine device) - Can be combined with other progestins
• Aromatase inhibitors - For advanced or recurrent disease in select cases

According to NCCN Guidelines, hormonal therapy is typically used for lower-grade endometrioid histologies with small tumor volume or slow growth patterns.

---

Radiation Therapy Advances

While not "new," radiation continues to play an important role:

• High-dose-rate brachytherapy - For medically inoperable patients
• Combined chemoradiation - Often paired with systemic therapy for high-risk cases
• Stereotactic ablative radiotherapy (SABR) - For oligometastatic disease (cancer in a few specific locations)

---

Key Questions to Ask Your Oncologist

1. Has my tumor been tested for mismatch repair deficiency, microsatellite instability, HER2 status, and other biomarkers? (This determines which newer treatments you're eligible for)

2. Am I a candidate for immunotherapy combinations, and if so, which one would you recommend for my specific situation?

3. What are the side effects of the treatment you're recommending, and how do they compare to other options?

4. If my cancer progresses on one treatment, what would be the next option?

5. Are there any clinical trials available for my type of endometrial cancer?

---

Important Context

The shift toward immunotherapy represents a major change in endometrial cancer treatment. According to NCCN Guidelines, these newer combinations are showing improved survival compared to traditional chemotherapy alone, particularly for advanced disease. However, the best treatment for YOUR specific situation depends on:

• Your cancer stage and grade
• Your tumor's genetic characteristics (biomarkers)
• Your overall health and ability to tolerate treatment
• Whether you've had previous treatments
• Your personal priorities and goals

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Authoritative Sources:

• NCCN Guidelines Version 1.2026 - Endometrial Carcinoma (most current)
• FDA Drug Approvals - Dostarlimab, pembrolizumab, durvalumab, and lenvatinib for endometrial cancer (2023-2024)
• Clinical Trial Data - RUBY, KEYNOTE-B21, DUO-E, and KEYNOTE-775 trials